Related Experiment Video
Updated: Mar 21, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Adults with cyanotic congenital heart disease: hematologic management
J K Perloff1, M H Rosove, J S Child
1UCLA Center for the Health Sciences.
Insights
Managing cyanotic adults with congenital heart disease requires attention to erythrocyte mass and oxygen transport. Guidelines focus on symptomatic hyperviscosity, iron deficiency, and renal function, not routine phlebotomy or antithrombotics.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Cyanotic congenital heart disease (CCHD) affects adults, yet practical hematologic management guidelines are scarce.
- Adults with CCHD present unique hematologic challenges requiring specialized care.
- Current understanding of hematologic issues in adult CCHD is limited, necessitating updated guidance.
Purpose of the Study:
- To provide practical therapeutic guidelines for the hematologic management of adults with CCHD.
- To consolidate observations on 124 adult patients with CCHD.
- To inform general physicians, cardiologists, and hematologists on managing CCHD-related hematologic complications.
Main Methods:
- Review of clinical observations from 124 adult patients with CCHD.
- Analysis of erythrocyte mass regulation, erythrocytosis, tissue oxygen transport, and hyperviscosity.
- Evaluation of iron deficiency, hemostasis, urate metabolism, and renal function in CCHD patients.
Main Results:
- Cerebral infarction was not observed in any patient.
- Phlebotomy is recommended only for symptomatic hyperviscosity.
- Iron therapy is indicated for symptomatic iron-deficient erythropoiesis.
- Abnormal hemostasis is common; antithrombotic medications have limited utility.
- Hyperuricemia is linked to renal uric acid excretion, not overproduction, and indicates renal dysfunction.
Conclusions:
- Hematologic management of adult CCHD should focus on addressing symptomatic complications rather than routine interventions.
- Phlebotomy should be reserved for symptomatic hyperviscosity, and iron therapy for iron deficiency.
- Hyperuricemia in CCHD patients serves as a marker for renal dysfunction, managed by promoting urate excretion.
Abstract:
Hematologic management of adults with cyanotic congenital heart disease has received little recent attention. The lack of practical therapeutic guidelines prompted us to consolidate our observations on 124 cyanotic adults for general physicians, cardiologists, and hematologists who care for these patients. Specific attention focused on regulation of erythrocyte mass and concepts of compensated and decompensated erythrocytosis, symptoms of deficient tissue oxygen transport, hyperviscosity and iron deficiency, the potential relation between elevated hematocrit levels and brain injury, hemostasis, urate metabolism, and renal function. Cerebral infarction was not seen in any patient. Phlebotomy is best reserved for treatment of symptomatic hyperviscosity. Iron therapy is indicated for symptomatic iron deficient erythropoiesis. Abnormal hemostatic mechanisms are the rule. Antithrombotic medications have little or no role in treatment. Hyperuricemia is the result of abnormal renal uric acid excretion not urate overproduction, and serves as a marker of abnormal renal function. Drugs that promote urate excretion are the preferred maintenance treatment in symptomatic hyperuricemic patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management

